## ULTA: Ulta Beauty, Inc. - XLY: Consumer Cyclical

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.5% in lower entry zone (4.0-10.0%), top 9% cross-sectional ranking. Short-term MRS_5 (1.4%) confirms momentum alignment. Outperforming sector by 4.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($577.91)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Ulta Beauty stock reaches all-time high at $612.42 By Investing.com**
- Source: Investing.com Nigeria | 20251222T201015 | Bullish | Relevance: 100%
- Ulta Beauty Inc. (ULTA) has reached an all-time high stock price of $612.42, demonstrating significant growth with a 42.37% surge over the past year. InvestingPro data highlights a 39.04% total return over the last year and a 26.17% gain in the past six months, contributing to a market capitalization of $27.09 billion. Despite its "GOOD" financial health, the stock's P/E ratio of 23.23 and PEG ratio of 4.95 suggest it may be overvalued compared to its InvestingPro Fair Value.

**2. Should DRMTLGY’s Exclusive Ulta Rollout Reshape Ulta Beauty’s (ULTA) Science‑Led Skincare Positioning?**
- Source: Simply Wall Street | 20251221T210840 | Somewhat-Bullish | Relevance: 100%
- Ulta Beauty's exclusive launch of DRMTLGY's clinical skincare line across its 1,400+ stores reinforces its commitment to science-led skincare, appealing to ingredient-conscious shoppers. While this deepens Ulta's focus on high-value products, it doesn't immediately alter its near-term earnings outlook, which still faces challenges from rising costs and competition and is projected to reach $13.8 billion revenue and $1.3 billion earnings by 2028, with a fair value of $603.43.

**3. Ulta Beauty (NASDAQ:ULTA) Hits New 1-Year High - Here's Why**
- Source: MarketBeat | 20251222T221452 | Bullish | Relevance: 100%
- Ulta Beauty (NASDAQ:ULTA) recently hit a new 52-week high of $612.75 after reporting strong Q3 earnings of $5.14 EPS and revenue of $2.86 billion, exceeding analyst estimates, and raising its FY2025 EPS guidance. The company also saw significant institutional investor interest and received a "Moderate Buy" consensus rating from analysts, with several firms increasing their price targets. This performance highlights Ulta's robust financial health and positive outlook in the specialty retail market.

**4. Ulta Beauty stock reaches all-time high at $612.42**
- Source: Investing.com India | 20251222T200908 | Bullish | Relevance: 100%
- Ulta Beauty Inc. stock has reached an all-time high of $612.42, marking a significant growth trajectory with a 42.37% surge over the past year. Despite appearing overvalued at a P/E ratio of 23.23 and PEG ratio of 4.95 compared to its InvestingPro Fair Value, the company maintains a "GOOD" financial health score and strong investor confidence. Analyst price targets have been raised following strong performance and strategic decisions, further indicating positive sentiment for Ulta Beauty.

**5. Ulta Beauty stock reaches all-time high at $612.42 By Investing.com**
- Source: Investing.com Canada | 20251222T200610 | Bullish | Relevance: 100%
- Ulta Beauty Inc. (ULTA) stock has reached an all-time high of $612.42, marking a 42.37% increase over the past year. Despite its strong performance and "GOOD" financial health, InvestingPro data suggests the stock is currently overvalued with a P/E ratio of 23.23 and a PEG ratio of 4.95. Analysts have recently raised price targets for Ulta Beauty, reflecting positive sentiment and strategic adjustments, including a new Executive Severance Plan.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 13, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Oppenheimer | $675 | $615 | +10% |
| 2025-12-08 | Morgan Stanley | $640 | $600 | +7% |
| 2025-12-08 | TD Cowen | $725 | $600 | +21% |
| 2025-12-05 | DA Davidson | $650 | $625 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Oppenheimer | main | Outperform |
| 2025-12-08 | Morgan Stanley | main | Overweight |
| 2025-12-08 | TD Cowen | up | Buy |
| 2025-12-05 | DA Davidson | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.6%)
- Blackrock Inc.: 9.0% (-2.1%)
- JPMORGAN CHASE & CO: 5.5% (+99.0%)
- State Street Corpora: 4.4% (+2.3%)
- Sanders Capital, LLC: 2.8% (+8.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 13 raises (avg +6%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.42 elevated, pricing in significant growth expectations. Forward P/E 21.7x stretched relative to 11% growth. Quality metrics strong (ROE 48%, ROA 15%). Analyst sentiment positive (13 raises, avg +6%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.5B |
| Beta | 0.87 |
| 52W Range | $309.01 - $613.16 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.42 |
| Forward P/E | 21.7 |
| Current P/E | 24.0 |
| YoY Growth | 10.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 6.5% (minimal 5-day change). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 90th percentile. MRS_5 at 1.4% confirms short-term momentum alignment. AM_20 at 7.1% shows strong absolute momentum above own 20MA. Outperforming sector by 4.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.93), confirming momentum. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.50% (CS: 91) | Strong |
| RSI_14 | 68.5 | Neutral |
| MACD Histogram | 1.93 | Bullish |
| vs SMA20 | 1.071x | Above |
| vs SMA50 | 1.132x | Above |
| vs SMA200 | 1.282x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $612.95
- **Stop Loss:** $577.91 (5.7% risk)
- **Target:** $665.51 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 25
- **Position Value:** $15,323.75
- **Portfolio %:** 15.32%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-03-12 (Est: $7.15)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $4.60 | $5.14 | +11.8% |
| 2025Q3 | $5.04 | $5.78 | +14.6% |
| 2025Q2 | $5.80 | $6.70 | +15.5% |
| 2025Q1 | $7.15 | $8.46 | +18.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*